GlobeNewswire Inc.··Sanofi And TevaSanofi and Teva Report Sustained Efficacy for Duvakitug in IBD Maintenance Study
Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease